

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

1287

PCT/EP 00 / 08580  
00/088 02



Eur päisches  
Patentamt

Eur pean  
Patent Office

Office européen  
des brevets

EP 00/8580

4

REC'D 17 OCT 2000

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99118956.4

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN  
THE HAGUE, 01/09/00  
LA HAYE, LE





Eur päisches  
Patentamt

European  
Patent Office

Office eur  
des brevets

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**

Anmeldung Nr.:  
Application no.:  
Demande n°: **99118956.4**

Anmeldetag:  
Date of filing:  
Date de dépôt: **27/09/99**

Anmelder:  
Applicant(s):  
Demandeur(s):  
**Degussa-Hüls Aktiengesellschaft**  
**60287 Frankfurt am Main**  
**GERMANY**

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:  
**Hydantoïn-racemase**

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:  
State:  
Pays:

Tag:  
Date:  
Date:

Aktenzeichen:  
File no.  
Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:

/

Anmeldetag benannte Vertragsstaaten:  
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques:



99118956.4

1

## Hydantoin-Racemase

### Description

The instant invention is directed to a hydantoin-racemase from *Arthrobacter aurescens* (DSM 3747, hyuA).

5 The production of optically pure amino carboxylic acids is of growing interest in agrochemical, food and pharmaceutical industry. In particular, the enzymatic hydrolysis of hydantoins is an attractive method for the synthesis of D- and L-amino acids with regard to low-cost  
10 starting material and complete turnover of substrate.

Several hydantoin degrading micro-organisms have been isolated and the enzymatic conversion of 5'-monosubstituted hydantoins was studied in detail (Syldatk and Pietzsch, 'Hydrolysis and formation of hydantoins' (1995), VCH  
15 Verlag, Weinheim, pp. 409-434; Ogawa et al., J. Mol. Catal. B: Enzym. 2 (1997), 163-176; Syldatk, C., May, O., Altenbuchner, J., Mattes, R. and Siemann, M. (1999) Microbiol. hydantoinases - industrial enzymes from the origin of life? Appl. Microbiol. Biotechnol. 51, 293-309).  
20 The asymmetric bio-conversion to either L- or D-amino acids consists of 3 steps:

- (i) chemical and/or enzymatic racemization of 5' substituted hydantoins,
- (ii) ring opening hydrolysis achieved by a  
25 hydantoinase and
- (iii) carbamoylase catalysed hydrolysis of the N-carbamoyl amino acid produced in the second step.

The chemical racemization of hydantoins proceeds via  
30 enolisation. The velocity depends on the electronic nature of the residue at the 5'-position (Ware, Chem. Rev. (1950),

46, 403-470) but usually, the racemization is a very slow process. For example, at room temperature and pH 8.5 only about 10 % of L-IMH is racemized to D-IMH in 20 hour (Syldatk et al., "Biocatalytic production of amino acids and derivatives" (1992), Hanser publishers, New York, pp. 75-176). The rate of racemization is increased by a very basic pH (>10) and high temperature (>80 °C).

At physiological conditions a high rate of racemization is achieved by hydantoin-specific racemases. So far, hydantoin racemases have been purified and characterised from *Arthrobacter* (Syldatk et al., "Biocatalytic production of amino acids and derivatives" (1992), Hanser publishers, New York, pp. 75-176; Syldatk et al., "Hydrolysis and formation of hydantoins" (1995), VCH Verlag, Weinheim, pp. 409-434) and a *Pseudomonas* species (Watabe et al., *J. Bacteriol.* (1992a), 174, 3461-3466; Watabe et al., *J. Bacteriol.* (1992b), 174, 7989-7995). Only the latter is also characterised in terms of nucleotide sequence and genetic organisation.

It was, therefore, an object of this invention to provide another rec-hydantoin-racemase, which is able to racemize hydantoins under physiological conditions with an acceptable rate for their implementation in a process for the production of enantiomerically enriched amino carboxylic acids on industrial scale.

Providing the recombinantly derived hydantoin-racemase from *Arthrobacter aurescens* DSM 3747 (Seq. 5) is responsible for the dispense from above mentioned task. Especially, the racemase according to the invention can advantageously be incorporated in a large scale process for the production of enantiomerically enriched amino carboxylic acids. The feasibility of providing the racemase in a recombinant manner is the clue for acceptance of this process in view of economic efficiency.



Furthermore, a gene (Seq. 4) encoding for the racemase according to the invention is protected. The gene with relation to the framework of this invention is seen as a group of genes comprising all possible genes encoding for the protein in question according to the degeneration of the genetic code.

In another embodiment this invention encompasses plasmids, vectors and micro-organisms, which comprise the gene of instant invention. Within the framework of this invention all plasmids, vectors and micro-organisms which could advantageously be used to carry out the invention and are known to the skilled worker are incorporated herewith. Especially, those mentioned in Studier et al., Methods Enzymol. 1990, 185, 61-69 or those presented in brochures of Novagen, Promega, New England Biolabs, Clontech or Gibco BRL are deemed to be suitable. More applicable plasmids, vectors can be found in:

DNA cloning: a practical approach. Volume I-III, edited by D. M. Glover, IRL Press Ltd., Oxford, Washington DC, 1985, 1987;

Denhardt, D. T. and Colasanti, J.: A surey of vectors for regulating expression of cloned DNA in E. coli. In: Rodriguez, R.L. and Denhardt, D. T (eds), Vectors, Butterworth, Stoneham, MA, 1987, pp179-204;

Gene expression technology. In: Goeddel, D. V. (eds), Methods in Enzymology, Volume 185, Academic Press, Inc., San Diego, 1990;

Sambrook, J., Fritsch, E.F. and Maniatis, T. 1989. Molecular cloning: a laboratory manual, 2<sup>nd</sup> ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.

In addition, primers useful for the amplification of the gene of the invention in a PCR are protected similarly. Primers which are feasible are for example:

S1137 5'-AGAACATATGAGAATCCTCGTGATCAA-3' (Seq. 1)

S1138 5'-AAAACTGCAGCTAGAGGTACTGCTTCTCTG-3' (Seq. 2)

Furthermore, all other primers which could serve to carry out this invention and which are known to the artisan are deemed to be useful in this sense. The finding of a suitable primer is done by comparison of known DNA-sequences or translation of amino acid sequences into the codon of the organism in question (e.g. for Streptomyces: Wright et al., Gene 1992, 113, 55-65). Similarities in amino acid sequences of proteins of so called superfamilies are useful in this regard, too (Firestone et al., Chemistry & Biology 1996, 3, 779-783). Additional information can be found in Oligonucleotide synthesis: a practical approach, edited by M.J. Gait, IRL Press Ltd, Oxford Washington DC, 1984; PCR Protocols: A guide to methods and applications, edited by M.A. Innis, D.H. Gelfound, J.J. Sninsky and T.J. White. Academic Press, Inc., San Diego, 1990. Those strategies are incorporated by reference herewith.

Another embodiment of this invention is the use of the racemase of the invention in a process for the production of amino carboxylic acids or derivatives thereof. Preferably, it is used according to the invention in a process for the production of enantiomerically enriched derivatives. Most preferably, the use is conducted in a covalent enzyme-membrane-reactor (DE19910691.6) or after non-covalent or covalent immobilisation to solid carriers (DE 197 033 14).

In order to prove the enzyme function, the gene was amplified by PCR from plasmid pAW16 using the primers S1137 and S1138 and placed under the control of a rhamnose promoter provided by the expression system pJOE2702. The resulting plasmid was designated pAW210 (Fig. 1). The E. coli cells harbouring pAW210 exhibited specific hydantoin racemase activities up to a maximum of 60 U/mg in crude

cell extracts (Fig. 2). The racemase activity was determined in crude extracts by polarimetry using 3 mM L-BH as substrate (Teves et al., Fresenius' J. Anal. Chem. 1999, 363, 738-743). An abundant protein of 31 kDa, representing approximately 10 % of the total cellular protein, was detected by SDS-PAGE analysis in rhamnose induced cells and was mainly in the soluble fraction of the crude cell extracts.

The plasmid pAW210 in E. coli JM109 was used for purification of the racemase. A two step procedure consisting of ammonium sulfate fractionation and MonoQ anion exchange chromatography was accomplished as described down under. The racemase was purified 10-fold to homogeneity, with 35 % overall recovery (Tab. 1).

Table 1: Purification of the racemase HyuA from E. Coli JM109 pAW210

Step	Volume [ml]	Protein- con. [mg/ml]	Volumetric activity [U/ml]	Specific activity [U/mg]	Total activity [U]	Purifica- tion [-fold]	Yield [%]
Crude extract	3	22.4	604	26.9	1812	1.0	100
(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	2.5	7	317	45.2	792	1.7	44
MonoQ <sup>a)</sup>	8.0	0.8	64	313.0	512	11.6	28

<sup>a)</sup> Protein was purified on MonoQ in 4 separate runs using 4 mg for each run.

The specific activity of the purified enzyme was determined by standard enzyme assay with D-Benzylhydantoin as substrate at 313 U/mg. In potassium phosphate buffer, pH 7.0 with 25 % glycerol, the purified enzyme could be stored for at least 6 months at -20 °C without noticeable loss of activity.

The matrix assisted laser desorption ionisation spectrum (MALDI) of the purified racemase gave a peak at a molecular mass of 25078.7. This is in good agreement with the calculated value of 25085 Da in contrast to the SDS-PAGE electrophoresis which gave a relative molecular mass of 31 kDa for the racemase monomer. On a calibrated column of superose 12 HR, the relative molecular mass of the native enzyme was estimated to be approximately 170 kDa  $\pm$  25. Due to the small subunit of 25 kDa and inaccuracy of the gel filtration method within this range the native enzyme is suggested to be either a hexamer, heptamer or octamer.

The effect of pH and temperature on the enzyme activity and stability are illustrated in Fig. 3-5. The pH optimum was determined between pH 8.0 and 9.0. Consequently, all standard assays were performed at pH 8.5. The optimum temperature for racemization of L-BH was around 55 °C, however the stability of the enzyme under assay conditions (Tris, pH 8.5) was only maintained up to 45 °C.

Racemization of the 5-substituted hydantoins BH, IMH and MTEH by HyuA was examined (Tab.2).

Table 2: Substrate specificity of HyuA

Substrate	Conc.	Relative Activity *)
	[mM]	[%]
L-MTEH	0.9	7
D-MTEH	0.9	8
L-BH	0.9	100
D-BH	0.9	95
L-IMH	0.9	13
D-IMH	0.9	12

\*) 100 % racemase activity corresponds to 313  $\mu$ /mg determined by standard assay

L- and D-BH gave the highest rates of activity, whereas the L- and D-isomer of MTEH were rather poorly racemised

indicating that aromatic hydantoins were preferred as substrates.

The  $K_M$  values of IMH and BH could not be determined due to the limited solubility of the substrates. Instead the

5 initial velocities at different concentrations of L-MTEH were measured. The kinetic plot (Fig.6) showed that the racemase is inhibited by the substrate L-MTEH. Even at low substrate concentrations (> 5 mM) inhibition is observed.

10 The microorganism *Arthrobacter aurescens* used for the invention was desposited at Deutsche Sammlung für Mikroorganismen under the accession number DSM 3747.

Examples:

- Bacterial strains, plasmids and growth conditions.** *E. coli* JM109 (Yanisch-Perron et al., Gene (1985), 33, 103-109) was used for cloning, sequencing and expression the *hyuA* gene from *Arthrobacter aureus* DSM 3747 (Groß et al., Biotech. Tech. (1987), 2, 85-90). *E. coli* strains were cultivated in 2xYT liquid broth or on 2xYT agar (Sambrook et al., Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbour Laboratory Press, New York). The media were supplemented with 100 µg/ml ampicillin to select plasmid carrying strains. The cultures were grown at 37°C, for *hyuA* expression the growth temperature was reduced to 30°C.
- General protocols.** All of the recombinant DNA techniques used were standard methods (Sambrook et al., Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbour Laboratory Press, New York). PCR reactions were performed with Taq DNA polymerase by following the recommendation by Roche Molecular Biochemicals. DNA sequencing was done from pUC-subclones with automated laser fluorescens DNA sequencer (Pharmacia LKB, Freiburg) by using AutoRead™ sequencing kit and M13 forward and reverse primer.
- Expression of *hyuA* in *E. coli*.** The racemase gene was amplified by PCR using the primers S1137 (5'-AGAACATATGAGAATCCTCGTGATCAA-3') and S1138 (5'-AAACTGCAGCTAGAGGTACTGCTTCTCTG-3') and pAW16 as template (Wilms et al., J. Biotechnol. (1999), 68, 101-113). The fragment was inserted between the NdeI and PstI sites of the expression vector pJOE2702 (Vollf et al., Mol. Microbiol. (1996), 21, 1037-1047) to create plasmid pAW210. Expression was induced by addition of 0.2 % rhamnose to

cultures at an optical density of 0.3 at 600 nm. After 6 h, cells corresponding to OD<sub>600</sub> of 10 were harvested, washed and resuspended in 1 ml desintegration buffer (0.07 M potassium phosphate, pH 7.0) and lysed by sonification (Ultrasonics sonicator, microtip, 2 x 30 s, duty cycle 50 % pulsed). Clarified extracts were obtained by centrifugation at 14000 rpm for 10 min.

**Enzyme assays.** Racemization of L-BH was measured by ORD-polarimetry (Model 341, Perkin Elmer Bodenseewerk, Überlingen, Germany) at a wavelength of 295 nm in the standard assay for racemase enzyme activity. 3 mM L-BH was dissolved in 0.1 M Tris, pH 3 at 45 °C in an ultrasonic waterbath, cooled to room temperature and the pH adjusted to pH 8.5 with 3 M NaOH. To 1 ml substrate solution 0.1 ml enzyme, diluted in 0.1 M Tris, pH 8.5, was added and the change in optical rotation determined at 37 °C by polarimetry (Teves et al., Fresenius' J. Anal. Chem. 1999, 363, 738-743). The racemization of MTEH and IMH by HyuA was determined at substrate concentrations of 0.9 mM and recorded by ORD at 253 nm and 334 nm. The specific activities were calculated from initial reaction rates which were determined according to Teves et al. (1999). For determination of enzyme activity by HPLC, 1 mM L-IMH was dissolved as described above. The mixture containing 900 µl enzyme solution was incubated 5 min at 37°C. The reaction was stopped by addition of 400 µl 14 % trichloroacetic acid and centrifugation in an Eppendorf centrifuge at full speed. 100 µl of the sample were diluted with 0.9 ml 0.1 M TrisHCl, pH 8.5, and D-IMH and L-IMH in the supernatant were separated by HPLC (Thermoseparation Products, Darmstadt, Germany) by injection of 20 µl sample into a Chiralpak WH-column (0.46x25 cm; Daicel Chemicals Industries LTD, Griesheim, Germany). The column was equilibrated with 0.25 mM CuSO<sub>4</sub>, pH 5.5. The flow rate was 1 ml/min at 50°C

and IMH detected at 254 nm. The chemical racemization of the substrate was taken into account. Racemization of 1  $\mu$ M substrate per minute was defined as one unit enzyme.

**Purification of recombinant hyuA.** For the preparation of crude extract, cells from 300 ml culture of rhamnose induced *E. coli* JM109 pAW210 were resuspended in 3 ml desintegration buffer and disrupted 3 times by french press (Amico, SLM Instruments Inc, Illinois, USA) at a pressure of 600 bar. Solid  $(\text{NH}_4)_2\text{SO}_4$  was gradually added to the cell-free extract to a concentration of 1.5 M and stirred 2 h at 4 °C. The precipitate formed was removed by centrifugation (Sorvall) and discarded. Another 0.7 M  $(\text{NH}_4)_2\text{SO}_4$  was added to the supernatant. The second precipitate obtained by centrifugation was resuspended in buffer A (10 mM potassium phosphate, pH 6.5) and applied to a MonoQ<sup>®</sup> HR 5/5 column equilibrated in buffer A and eluted with a linear gradient of 0 to 1.0 M NaCl in buffer A. HyuA was eluted at a concentration of 0.37 M NaCl. Peak fractions were pooled and dialyzed against desintegration buffer, glycerol was added to a final concentration of 25 % and stored at -20 °C.

**Protein characterisation.** Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was done according to the method of Laemmli (Laemmli, Nature (1970), 227, 680-685). Protein concentrations were determined by the method of Bradford (Bradford, Anal. Biochem. (1976), 72, 248-254) using the Biorad protein assay dye reagent concentrate. Standard curves were generated with bovine serum albumin. The  $M_r$  of native protein was determined by gel filtration using superosel2HR column as described previously (Wilms et al., J. Biotechnol. (1999), 68, 101-113), the column was equilibrated and eluted with buffer consisting of 0.1 M potassium phosphate and 0.1 M NaCl, pH 7. The pH profile of the purified racemase was



measured between the pH range 7.0 to 9.5 in Tris buffer. The substrate was dissolved in 0.1 M Tris, pH 3 at 45 °C using an ultrasonic waterbath. After cooling to room temperature, the pH was adjusted to the desired pH with sodium hydroxide and enzyme activity was determined using the standard assay. The reaction temperature optimum of purified racemase was determined using temperatures between 25 and 65 °C in the standard assay. The stability of the enzyme was measured after preincubation at temperatures between 25 and 70 °C for 15 minutes in the presence of desintegration buffer and 0.1 M Tris buffer, pH 8.5, respectively. The increased chemical racemization at high pH and temperatures, respectively, was considered. The effect of EDTA, DTT, HgCl<sub>2</sub> and iodoacetamid on HyuA was tested by incubation of respective substance (10 mM) and purified enzyme (12 µg) in desintegration buffer (final volume 20 µl) at 30°C. After 1 h specific activities were determined by the standard enzyme assay.

**Hydantoin-Racemase**

**Claims**

1. rec-Hydantoin-racemase from *Arthrobacter aureus* DSM 3747.

---

- 5 2. Gene encoding for the racemase according to claim 1.
3. Vector comprising the gene according to claim 2.
4. Microorganism comprising the gene according to claim 2.
5. Primer for a gene according to claim 2.
- 10 6. Use of the racemase according to claim 1 in a process for the production of amino carboxylic acids or derivatives thereof.
7. Use according to claim 6 in a process for the production of enantiomerically enriched compounds.
- 15 8. Use according to claim 6 and/or 7, characterised in that, the process is conducted in a enzyme-membrane-reactor.

990097 AM

SEQUENCE LISTING

<110> Degussa-Hüls Aktiengesellschaft

5 <120> Hydantoin-Racemase

<130> 990097 AM

<140>

10 <141>

<160> 5

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 27

<212> DNA

20 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer 1137

25 <400> 1

agaacatatg agaatcctcg tgatcaa

27

<210> 2

<211> 30

30 <212> DNA

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: Primer 1138

<400> 2

aaaactgcag ctagaggtac tgcttctctg

30

<210> 3

40 <211> 711

<212> DNA

<213> Arthrobacter aurescens

<220>

45 <221> CDS

<222> (1)..(711)

<400> 3

50 atg aga atc ctc gtg atc aac ccc aac agt tcc agc gcc ctt act gaa 48  
Met Arg Ile Leu Val Ile Asn Pro Asn Ser Ser Ser Ala Leu Thr Glu  
1 5 10 15

55 tcg gtt gcg gac gca gca caa caa gtt gtc gcg acc gcc acc ata att 96  
Ser Val Ala Asp Ala Ala Gln Gln Val Val Ala Thr Gly Thr Ile Ile  
20 25 30

tct gcc atc aac ccc tcc aga gga ccc gcc gtc att gaa gcc agc ttt 144  
Ser Ala Ile Asn Pro Ser Arg Gly Pro Ala Val Ile Glu Gly Ser Phe  
35 40 45

13

5	gac gaa gca ctg gcc acg ttc cat ctc att gaa gag gtg gag cgc gct Asp Glu Ala Leu Ala Thr Phe His Leu Ile Glu Glu Val Glu Arg Ala 50 55 60	192
10	gag cgg gaa aac ccg ccc gac gcc tac gtc atc gca tgt ttc ggg gat Glu Arg Glu Asn Pro Pro Asp Ala Tyr Val Ile Ala Cys Phe Gly Asp 65 70 75 80	240
15	ccg gga att gac geg gtc aag gag ctg act gac agg cca gtg gta gga Pro Gly Leu Asp Ala Val Lys Glu Leu Thr Asp Arg Pro Val Val Gly 85 90 95	288
20	gtt gcc gaa gct gca atc cac atg tct tca ttc gtc gcg gcc acc ttc Val Ala Glu Ala Ala Ile His Met Ser Ser Phe Val Ala Ala Thr Phe 100 105 110	336
25	tcc att gtc agc atc ctc ccg agg gtc agg aaa cat ctg cac gaa ctg Ser Ile Val Ser Ile Leu Pro Arg Val Arg Lys His Leu His Glu Leu 115 120 125	384
30	gta cgg caa gcg ggg gcg acg aat cgc ctc gcc tcc atc aag ctc cca Val Arg Gln Ala Gly Ala Thr Asn Arg Leu Ala Ser Ile Lys Leu Pro 130 135 140	432
35	aat ctg ggg gtg atg gcc ttc cat gag gac gaa cat gcc gca ctg gag Asn Leu Gly Val Met Ala Phe His Glu Asp Glu His Ala Ala Leu Glu 145 150 155 160	480
40	acg ctc aaa caa gcc gcc aag gag gcg gtc cag gag gac ggc gcc gag Thr Leu Lys Gln Ala Ala Lys Glu Ala Val Gln Glu Asp Gly Ala Glu 165 170 175	528
45	tcg ata gtg ctc gga tgc gcc ggc atg gtg ggg ttt gcg cgt caa ctg Ser Ile Val Leu Gly Cys Ala Gly Met Val Gly Phe Ala Arg Gln Leu 180 185 190	576
50	agc gac gaa ctc ggc gtc cct gtc atc gac ccc gtc gag gca gct tgc Ser Asp Glu Leu Gly Val Pro Val Ile Asp Pro Val Glu Ala Ala Cys 195 200 205	624
55	cgc gtg gcc gag agt ttg gtc gct ctg ggc tac cag acc agc aaa gcg Arg Val Ala Glu Ser Leu Val Ala Leu Gly Tyr Gln Thr Ser Lys Ala 210 215 220	672
60	aac tcg tat caa aaa ccg aca gag aag cag tac ctc tag Asn Ser Tyr Gln Lys Pro Thr Glu Lys Gln Tyr Leu 225 230 235	711
65	<210> 4 <211> 237 <212> PRT <213> Arthrobacter aureescens	
70	<400> 4 Met Arg Ile Leu Val Ile Asn Pro Asn Ser Ser Ser Ala Leu Thr Glu 1 5 10 15	

14

Ser Val Ala Asp Ala Ala Gln Gln Val Val Ala Thr Gly Thr Ile Ile  
20 25 30

5 Ser Ala Ile Asn Pro Ser Arg Gly Pro Ala Val Ile Glu Gly Ser Phe  
35 40 45

Asp Glu Ala Leu Ala Thr Phe His Leu Ile Glu Glu Val Glu Arg Ala  
50 55 60

---

10 Glu Arg Glu Asn Pro Pro Asp Ala Tyr Val Ile Ala Cys Phe Gly Asp  
65 70 75 80

Pro Gly Leu Asp Ala Val Lys Glu Leu Thr Asp Arg Pro Val Val Gly  
85 90 95

15 Val Ala Glu Ala Ala Ile His Met Ser Ser Phe Val Ala Ala Thr Phe  
100 105 110

20 Ser Ile Val Ser Ile Leu Pro Arg Val Arg Lys His Leu His Glu Leu  
115 120 125

Val Arg Gln Ala Gly Ala Thr Asn Arg Leu Ala Ser Ile Lys Leu Pro  
130 135 140

25 Asn Leu Gly Val Met Ala Phe His Glu Asp Glu His Ala Ala Leu Glu  
145 150 155 160

Thr Leu Lys Gln Ala Ala Lys Glu Ala Val Gln Glu Asp Gly Ala Glu  
165 170 175

30 Ser Ile Val Leu Gly Cys Ala Gly Met Val Gly Phe Ala Arg Gln Leu  
180 185 190


Ser Asp Glu Leu Gly Val Pro Val Ile Asp Pro Val Glu Ala Ala Cys  
195 200 205

Arg Val Ala Glu Ser Leu Val Ala Leu Gly Tyr Gln Thr Ser Lys Ala  
210 215 220

40 Asn Ser Tyr Gln Lys Pro Thr Glu Lys Gln Tyr Leu  
225 230 235


1/4

Fig. 1



2/4

Fig. 2



3 / 4

Fig. 3






Fig. 4



5 Fig. 5






990097 AM

4 / 4

Fig. 6



## Hydantoin-Racemase

### Abstract

The instant invention is directed to a rec-hydantoin-racemase from *Arthrobacter aurescens* DSM 3747.

- 5 Furthermore, the gene encoding for the racemase and plasmids, vectors and microorganisms comprising this gene are to be protected.

Use in a process for the production of amino carboxylic acids or derivatives thereof.